首页> 外文OA文献 >Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)

【2h】

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)

机译：PSC-833（Valspodar）与长春酮，多柔比蛋白和地塞米松（Valspodar / VAD）组合的III次研究与患有重复或难治多骨髓瘤的患者（E1A95）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
William R. Friedenberg; Montserrat Rue; Emily A. Blood; William S. Dalton; Chaim Shustik; Richard A. Larson; Pieter Sonneveld; Philip R. Greipp;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. A prospective comparative study of efficacy of lenalidomide plus dexamethasone combination therapy versus VAD (vincristine, doxorubicin and dexamethasone) regimen in the treatment of multiple myeloma [J] . S. Remya, M. J. Sudha, Bindulatha R. Nair, International Journal of Basic & Clinical Pharmacology . 2017,第3期

机译：来那度胺联合地塞米松联合治疗与VAD（长春新碱，阿霉素和地塞米松）方案治疗多发性骨髓瘤疗效的前瞻性比较研究
2. A PROSPECTIVE COMPARATIVE STUDY OF SAFETY OF LENALIDOMIDE PLUS DEXAMETHASONE COMBINATION THERAPY VERSUS VAD (VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE) REGIMEN IN THE TREATMENT OF MULTIPLE MYELOMA [J] . S. Remya, M. J. Sudha, R. B. Nair, International Journal of Pharmaceutical Sciences and Research . 2017,第11期

机译：来那度联用地塞米松联合治疗对VAD（长春新碱，阿霉素和地塞米松）方案在多发性骨髓瘤治疗中的安全性进行前瞻性比较研究
3. Acute Pancreatitis Following VAD Chemotherapy Combination Consisting Of Vincristine, Doxorubicin, And Dexamethasone In A Newly Diagnosed Multiple Myeloma Patient: A Case Report. [J] . Selami Kocak Toprak, Serkan Ocal, Betul Erismis, The Internet Journal of Oncology . 2012,第2期

机译：在新诊断的多发性骨髓瘤患者中，长春新碱，阿霉素和地塞米松联合VAD化疗后的急性胰腺炎：病例报告。
4. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
5. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma [O] . Ivan Spicka, Enrique M. Ocio, Heather E. Oakervee, -1

机译：复发性/难治性多发性骨髓瘤患者中普立体蛋白酶联合地塞米松和地塞米松的随机III期研究（ADMYRE）
6. A prospective comparative study of efficacy of lenalidomide plus dexamethasone combination therapy versus VAD (vincristine, doxorubicin and dexamethasone) regimen in the treatment of multiple myeloma [O] . S. Remya, M. J. Sudha, Bindulatha R. Nair, 2017

机译：半任明奈多加地塞米松组合治疗与VAD（血管素，多柔比蛋白和地塞米松）治疗多发性骨髓瘤治疗的前瞻性比较研究

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)

著录项

引文网络

相似文献

相关主题

期刊订阅